352 research outputs found
Letter by Andreotti et al Regarding Article, "Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin Intolerance"
No full textN/
Antithrombotic therapy for patients with atrial fibrillation and atherothrombotic vascular disease: striking the right balance between efficacy and safety
No full textAtrial fibrillation (AF), the most prevalent cardiac arrhythmia, is estimated to affect 1.5% to 2.0% of the general population, that is, at least 100 million people worldwide.1 Left untreated, patients with nonvalvular AF (NVAF) are exposed to an annual risk of thromboembolic stroke of ≈5%, resulting in 5 million AF-related strokes each year.1 Properly dosed anticoagulation (eg, warfarin adjusted to an international normalized ratio of 2.0–3.0) is extremely effective in preventing AF-related strokes, reducing risk by two thirds compared with no therapy and by one-half compared with aspirin.1 In contrast, aspirin alone achieves a 21% relative reduction in risk of nonfatal stroke compared with no treatment, and aspirin plus clopidogrel yields an additional 11% reduction compared with aspirin alone.1 Thus, anticoagulation is the unchallenged current treatment of choice for patients with NVAF at moderate to high risk of thromboembolic complications
Direct oral anticoagulants for ventricular thrombus resolution: pilot trials show reassuring efficacy and safety compared to warfarin
No full textN/
Expanding the role of coagulation in arterial thrombosis: evidence from animal models using a new factor Xa inhibitor
No full textN/
Cancer unmasked by bleeding during anticoagulant therapy: when a problem may become an opportunity
No full textN/
- …
